QIAGEN Files 6-K, Reports Unaudited Q4 & FY 2023 Results

TL;DR

**QIAGEN just dropped its Q4 and full-year 2023 earnings, check the press release for details!**

AI Summary

QIAGEN N.V. (NYSE: QGEN) filed a 6-K on February 8, 2024, to announce its unaudited financial results for the fourth quarter and full year ended December 31, 2023. The company issued a press release on February 6, 2024, detailing these results, including non-GAAP adjusted figures which they use to provide additional insight into their financial performance. This matters to investors because it provides the latest financial health update, allowing them to assess the company's performance against expectations and make informed decisions about their investment in QGEN.

Why It Matters

This filing provides investors with QIAGEN's latest financial performance data, crucial for evaluating the company's health and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of financial results and does not introduce new, significant risks.

Analyst Insight

An investor should review the full press release (Exhibit 99.1) to understand the specific financial performance metrics for Q4 and FY 2023, paying close attention to both GAAP and non-GAAP adjusted results, and compare them against analyst expectations and historical performance to assess the company's trajectory.

Key Players & Entities

• QIAGEN N.V. (company) — the registrant filing the 6-K
• February 6, 2024 (date) — date QIAGEN issued the press release
• December 31, 2023 (date) — end of the quarterly and annual reporting period
• NYSE: QGEN (company) — QIAGEN's stock ticker on the New York Stock Exchange
• Frankfurt, Prime Standard: QIA (company) — QIAGEN's stock ticker on the Frankfurt Stock Exchange

FAQ

Key Financial Figures

• $509 million — al profitability Q4 2023 Net sales of $509 million (+2% actual rates, +1% constant exchang
• $0.42 — ant exchange rates, CER) diluted EPS of $0.42 and adjusted diluted EPS of $0.55 ($0.5
• $0.55 — PS of $0.42 and adjusted diluted EPS of $0.55 ($0.55 CER vs. $0.53 CER outlook) FY
• $0.53 — ted diluted EPS of $0.55 ($0.55 CER vs. $0.53 CER outlook) FY 2023 Achieved outlook
• $1.97 billion — FY 2023 Achieved outlook for at least $1.97 billion CER sales and at least $2.07 CER adj. E
• $2.07 — st $1.97 billion CER sales and at least $2.07 CER adj. EPS, +8% CER sales growth in n
• $2.0 billion — come margin 2024 outlook for at least $2.0 billion CER net sales adj. diluted EPS of at le
• $2.10 — net sales adj. diluted EPS of at least $2.10 CER, reflects adj. operating income mar
• $503 million — full-year 2023. Net sales results of $503 million at constant exchange rates (CER) for Q4
• $500 million — 2023 achieved the outlook for at least $500 million CER, driven by 8% CER growth in the non
• $1.97 b — ER. Full-year 2023 sales declined 8% to $1.97 billion, achieving the outlook for $1.97
• $2.09 — oduct groups. Adjusted diluted EPS were $2.09 CER and exceeded the outlook for at lea
• $300 million — ng benefits from the recently completed $300 million synthetic share repurchase. We closed
• $0.39 — 10 % 341 423 -19 % Diluted EPS $0.42 $0.39 8 % $1.48 $1.84 -20 % Diluted shares (
• $1.48 — 423 -19 % Diluted EPS $0.42 $0.39 8 % $1.48 $1.84 -20 % Diluted shares (in million

Filing Documents

• a2023q4pr6-k.htm (6-K) — 510KB
• qiagen_logo.jpg (GRAPHIC) — 68KB
• 0001015820-24-000008.txt ( ) — 604KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. QIAGEN N.V. By s Roland Sackers Roland Sackers Chief Financial Officer Date February 8, 2024 4 Table of Contents EXHIBIT INDEX Exhibit No. Exhibit 99.1 Press Release dated February 6, 2024 5 Exhibit 99.1 Media Release QIAGEN exceeds outlook for Q4 2023, led by 8% CER sales growth in non-COVID products and improved operational profitability Q4 2023 Net sales of $509 million (+2% actual rates, +1% constant exchange rates, CER) diluted EPS of $0.42 and adjusted diluted EPS of $0.55 ($0.55 CER vs. $0.53 CER outlook) FY 2023 Achieved outlook for at least $1.97 billion CER sales and at least $2.07 CER adj. EPS, +8% CER sales growth in non-COVID portfolio and 27% adj. operating income margin 2024 outlook for at least $2.0 billion CER net sales adj. diluted EPS of at least $2.10 CER, reflects adj. operating income margin gains but significant non-operating income pressure Venlo, the Netherlands, February 6, 2024 - QIAGEN N.V. (NYSE QGEN Frankfurt Prime Standard QIA) announced results for the fourth quarter and full-year 2023. Net sales results of $503 million at constant exchange rates (CER) for Q4 2023 achieved the outlook for at least $500 million CER, driven by 8% CER growth in the non-COVID-19 portfolio. Total sales for Q4 2023 rose 2% (+1% CER) to $509 million from Q4 2022, a period marked by significant COVID-19 sales. Adjusted diluted earnings per share (EPS) were $0.55 CER and above the outlook for at least $0.53 CER. Full-year 2023 sales declined 8% to $1.97 billion, achieving the outlook for $1.97 billion CER sales and were supported by 8% CER growth for non-COVID product groups. Adjusted diluted EPS were $2.09 CER and exceeded the outlook for at least $2.07 CER. For 2024, QIAGEN has set an outlook for net sales of at least $2.0 bi

View Full Filing

View this 6-K filing on SEC EDGAR